Cargando…
A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems
BACKGROUND: Antimicrobial resistance is an urgent global healthcare concern. Beyond carbapenems as broad-spectrum, often ‘last resort’ antibiotics, oral penem antibiotics currently are approved only in Japan and India, used for the treatment of indications including urinary tract infections (UTIs)....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777757/ https://www.ncbi.nlm.nih.gov/pubmed/36570688 http://dx.doi.org/10.1093/jacamr/dlac125 |
_version_ | 1784856184700796928 |
---|---|
author | Gandra, Sumanth Takahashi, Satoshi Mitrani-Gold, Fanny S Mulgirigama, Aruni Ferrinho, Diogo A |
author_facet | Gandra, Sumanth Takahashi, Satoshi Mitrani-Gold, Fanny S Mulgirigama, Aruni Ferrinho, Diogo A |
author_sort | Gandra, Sumanth |
collection | PubMed |
description | BACKGROUND: Antimicrobial resistance is an urgent global healthcare concern. Beyond carbapenems as broad-spectrum, often ‘last resort’ antibiotics, oral penem antibiotics currently are approved only in Japan and India, used for the treatment of indications including urinary tract infections (UTIs). Exploring oral penem use to better understand the impact of antibiotic resistance on public health would help inform the management of infectious diseases, including UTIs. SCOPING REVIEW METHODOLOGY: This scoping review investigated the impact of faropenem and other oral penems on Enterobacterales infection treatment and evaluated evidence for faropenem resistance and cross-resistance to carbapenems. PubMed, Embase, J-STAGE and CiNii were searched for relevant English- or Japanese-language articles published between 1 January 1996 and 6 August 2021. KEY FINDINGS: From 705 unique publications, 29 eligible articles were included (16 in vitro studies; 10 clinical trials; 2 in vitro and in vivo studies; and 1 retrospective medical chart review). Limited evidence described faropenem to treat infectious disease; only four randomized clinical trials were identified. Faropenem dosing regimens varied broadly within and between indications. One study indicated potential dependence of penem efficacy on underlying antibiotic resistance mechanisms, while several studies reported UTI persistence or recurrence after faropenem treatment. In vitro MIC data suggested some potential bacterial resistance to faropenem, while limited clinical data showed resistance emergence after faropenem treatment. Preliminary in vitro evidence suggested faropenem resistance might foster cross-resistance to carbapenems. Overall, very limited clinical evidence describes faropenem for treating infectious diseases. Preclinical and clinical research investment and dedicated community surveillance monitoring is crucial for understanding faropenem treatment patterns, resistance and potential cross-resistance to carbapenems. |
format | Online Article Text |
id | pubmed-9777757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97777572022-12-23 A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems Gandra, Sumanth Takahashi, Satoshi Mitrani-Gold, Fanny S Mulgirigama, Aruni Ferrinho, Diogo A JAC Antimicrob Resist Systematic Review BACKGROUND: Antimicrobial resistance is an urgent global healthcare concern. Beyond carbapenems as broad-spectrum, often ‘last resort’ antibiotics, oral penem antibiotics currently are approved only in Japan and India, used for the treatment of indications including urinary tract infections (UTIs). Exploring oral penem use to better understand the impact of antibiotic resistance on public health would help inform the management of infectious diseases, including UTIs. SCOPING REVIEW METHODOLOGY: This scoping review investigated the impact of faropenem and other oral penems on Enterobacterales infection treatment and evaluated evidence for faropenem resistance and cross-resistance to carbapenems. PubMed, Embase, J-STAGE and CiNii were searched for relevant English- or Japanese-language articles published between 1 January 1996 and 6 August 2021. KEY FINDINGS: From 705 unique publications, 29 eligible articles were included (16 in vitro studies; 10 clinical trials; 2 in vitro and in vivo studies; and 1 retrospective medical chart review). Limited evidence described faropenem to treat infectious disease; only four randomized clinical trials were identified. Faropenem dosing regimens varied broadly within and between indications. One study indicated potential dependence of penem efficacy on underlying antibiotic resistance mechanisms, while several studies reported UTI persistence or recurrence after faropenem treatment. In vitro MIC data suggested some potential bacterial resistance to faropenem, while limited clinical data showed resistance emergence after faropenem treatment. Preliminary in vitro evidence suggested faropenem resistance might foster cross-resistance to carbapenems. Overall, very limited clinical evidence describes faropenem for treating infectious diseases. Preclinical and clinical research investment and dedicated community surveillance monitoring is crucial for understanding faropenem treatment patterns, resistance and potential cross-resistance to carbapenems. Oxford University Press 2022-12-22 /pmc/articles/PMC9777757/ /pubmed/36570688 http://dx.doi.org/10.1093/jacamr/dlac125 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Systematic Review Gandra, Sumanth Takahashi, Satoshi Mitrani-Gold, Fanny S Mulgirigama, Aruni Ferrinho, Diogo A A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems |
title | A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems |
title_full | A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems |
title_fullStr | A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems |
title_full_unstemmed | A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems |
title_short | A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems |
title_sort | systematic scoping review of faropenem and other oral penems: treatment of enterobacterales infections, development of resistance and cross-resistance to carbapenems |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777757/ https://www.ncbi.nlm.nih.gov/pubmed/36570688 http://dx.doi.org/10.1093/jacamr/dlac125 |
work_keys_str_mv | AT gandrasumanth asystematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT takahashisatoshi asystematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT mitranigoldfannys asystematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT mulgirigamaaruni asystematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT ferrinhodiogoa asystematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT gandrasumanth systematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT takahashisatoshi systematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT mitranigoldfannys systematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT mulgirigamaaruni systematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems AT ferrinhodiogoa systematicscopingreviewoffaropenemandotheroralpenemstreatmentofenterobacteralesinfectionsdevelopmentofresistanceandcrossresistancetocarbapenems |